Literature DB >> 25329375

Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer.

Ken-Ichi Takayama1, Takashi Suzuki, Shuichi Tsutsumi, Tetsuya Fujimura, Satoru Takahashi, Yukio Homma, Tomohiko Urano, Hiroyuki Aburatani, Satoshi Inoue.   

Abstract

The transcriptional network of the androgen receptor (AR), a key molecule of prostate cancer, is frequently modulated by interactions with other transcriptional factors such as forkhead box protein A1 (FOXA1). However, global regulatory mechanisms of AR signaling mediated by such factors have not been well investigated. Here we conducted a chromatin immunoprecipitation sequence analysis, which revealed that another FOX family, FOXP1, is specifically regulated by both AR and FOXA1. We also found that FOXP1 acts as a tumor suppressor in prostate cancer through inhibiting cell proliferation and migration. We generated an extensive global map of FOXP1 binding sites and found that FOXP1 is directly involved in AR-mediated transcription. We demonstrated that FOXP1 has a repressive effect on AR-induced transcriptional activity or histone modification in enhancer regions. Moreover, by a global analysis of androgen-mediated transcriptional networks, we observed enrichment of FOXP1 binding genes in the gene cluster negatively regulated by FOXP1. Evaluation of FOXP1 expression in clinical samples indicated that the decreased expression of FOXP1 is another prognostic factor of prostate cancer. Taken together, our results suggest a novel mechanism in which AR-induced FOXP1 functions as a direct modulator of the AR and FOXA1 centric global transcriptional network.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25329375      PMCID: PMC5414778          DOI: 10.1210/me.2014-1171

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  27 in total

1.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

2.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Authors:  Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

3.  The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.

Authors:  A H Banham; N Beasley; E Campo; P L Fernandez; C Fidler; K Gatter; M Jones; D Y Mason; J E Prime; P Trougouboff; K Wood; J L Cordell
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 4.  Androgen receptor (AR) aberrations in castration-resistant prostate cancer.

Authors:  Kati K Waltering; Alfonso Urbanucci; Tapio Visakorpi
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

Review 5.  Cancer genetics and genomics of human FOX family genes.

Authors:  Masuko Katoh; Maki Igarashi; Hirokazu Fukuda; Hitoshi Nakagama; Masaru Katoh
Journal:  Cancer Lett       Date:  2012-09-27       Impact factor: 8.679

6.  Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.

Authors:  Peck Yean Tan; Cheng Wei Chang; Kern Rei Chng; K D Senali Abayratna Wansa; Wing-Kin Sung; Edwin Cheung
Journal:  Mol Cell Biol       Date:  2011-11-14       Impact factor: 4.272

7.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.

Authors:  Ken-ichi Takayama; Shuichi Tsutsumi; Takashi Suzuki; Kuniko Horie-Inoue; Kazuhiro Ikeda; Kiyofumi Kaneshiro; Tetsuya Fujimura; Jinpei Kumagai; Tomohiko Urano; Yoshiyuki Sakaki; Katsuhiko Shirahige; Hironobu Sasano; Satoru Takahashi; Tadaichi Kitamura; Yasuyoshi Ouchi; Hiroyuki Aburatani; Satoshi Inoue
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

10.  Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer.

Authors:  Ken-Ichi Takayama; Kuniko Horie-Inoue; Shintaro Katayama; Takashi Suzuki; Shuichi Tsutsumi; Kazuhiro Ikeda; Tomohiko Urano; Tetsuya Fujimura; Kiyoshi Takagi; Satoru Takahashi; Yukio Homma; Yasuyoshi Ouchi; Hiroyuki Aburatani; Yoshihide Hayashizaki; Satoshi Inoue
Journal:  EMBO J       Date:  2013-05-03       Impact factor: 11.598

View more
  28 in total

1.  Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.

Authors:  D Obinata; K Takayama; K Fujiwara; T Suzuki; S Tsutsumi; N Fukuda; H Nagase; T Fujimura; T Urano; Y Homma; H Aburatani; S Takahashi; S Inoue
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

2.  6-gene promoter methylation assay is potentially applicable for prostate cancer clinical staging based on urine collection following prostatic massage.

Authors:  Kostyantyn A Nekrasov; Mark V Vikarchuk; Evgeniya E Rudenko; Igor V Ivanitskiy; Viacheslav M Grygorenko; Rostyslav O Danylets; Alexander G Kondratov; Liubov A Stoliar; Bizhan R Sharopov; Volodymyr I Kashuba
Journal:  Oncol Lett       Date:  2019-10-29       Impact factor: 2.967

3.  The Immunogenetics of Non-melanoma Skin Cancer.

Authors:  Sabha Mushtaq
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression.

Authors:  Ken-ichi Takayama; Aya Misawa; Takashi Suzuki; Kiyoshi Takagi; Yoshihide Hayashizaki; Tetsuya Fujimura; Yukio Homma; Satoru Takahashi; Tomohiko Urano; Satoshi Inoue
Journal:  Nat Commun       Date:  2015-09-25       Impact factor: 14.919

5.  miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.

Authors:  Zhenhua Hu; Mingbo Cai; Ying Zhang; Lingling Tao; Ruixia Guo
Journal:  Cell Cycle       Date:  2019-12-29       Impact factor: 4.534

6.  Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

Authors:  David C Wedge; Gunes Gundem; Thomas Mitchell; Dan J Woodcock; Inigo Martincorena; Mohammed Ghori; Jorge Zamora; Adam Butler; Hayley Whitaker; Zsofia Kote-Jarai; Ludmil B Alexandrov; Peter Van Loo; Charlie E Massie; Stefan Dentro; Anne Y Warren; Clare Verrill; Dan M Berney; Nening Dennis; Sue Merson; Steve Hawkins; William Howat; Yong-Jie Lu; Adam Lambert; Jonathan Kay; Barbara Kremeyer; Katalin Karaszi; Hayley Luxton; Niedzica Camacho; Luke Marsden; Sandra Edwards; Lucy Matthews; Valeria Bo; Daniel Leongamornlert; Stuart McLaren; Anthony Ng; Yongwei Yu; Hongwei Zhang; Tokhir Dadaev; Sarah Thomas; Douglas F Easton; Mahbubl Ahmed; Elizabeth Bancroft; Cyril Fisher; Naomi Livni; David Nicol; Simon Tavaré; Pelvender Gill; Christopher Greenman; Vincent Khoo; Nicholas Van As; Pardeep Kumar; Christopher Ogden; Declan Cahill; Alan Thompson; Erik Mayer; Edward Rowe; Tim Dudderidge; Vincent Gnanapragasam; Nimish C Shah; Keiran Raine; David Jones; Andrew Menzies; Lucy Stebbings; Jon Teague; Steven Hazell; Cathy Corbishley; Johann de Bono; Gerhardt Attard; William Isaacs; Tapio Visakorpi; Michael Fraser; Paul C Boutros; Robert G Bristow; Paul Workman; Chris Sander; Freddie C Hamdy; Andrew Futreal; Ultan McDermott; Bissan Al-Lazikani; Andrew G Lynch; G Steven Bova; Christopher S Foster; Daniel S Brewer; David E Neal; Colin S Cooper; Rosalind A Eeles
Journal:  Nat Genet       Date:  2018-04-16       Impact factor: 38.330

7.  FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.

Authors:  Eun Jung Choi; Eun Jin Seo; Dae Kyoung Kim; Su In Lee; Yang Woo Kwon; Il Ho Jang; Ki-Hyung Kim; Dong-Soo Suh; Jae Ho Kim
Journal:  Oncotarget       Date:  2016-01-19

8.  Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma.

Authors:  Harvind S Chahal; Wenting Wu; Katherine J Ransohoff; Lingyao Yang; Haley Hedlin; Manisha Desai; Yuan Lin; Hong-Ji Dai; Abrar A Qureshi; Wen-Qing Li; Peter Kraft; David A Hinds; Jean Y Tang; Jiali Han; Kavita Y Sarin
Journal:  Nat Commun       Date:  2016-08-19       Impact factor: 14.919

9.  Uncovering Direct Targets of MiR-19a Involved in Lung Cancer Progression.

Authors:  Kumiko Yamamoto; Sachio Ito; Hiroko Hanafusa; Kenji Shimizu; Mamoru Ouchida
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

10.  Downregulation of FOXP1 Inhibits Cell Proliferation in Hepatocellular Carcinoma by Inducing G1/S Phase Cell Cycle Arrest.

Authors:  Xin Wang; Ji Sun; Meiling Cui; Fangyu Zhao; Chao Ge; Taoyang Chen; Ming Yao; Jinjun Li
Journal:  Int J Mol Sci       Date:  2016-09-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.